ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Rituximab for the treatment of idiopathic membranous nephropathy with nephrotic syndrome: a systematic review and meta-analysis

You, Lu; Ye, Peiyi; Xiao, Guanqing; Liang, Jiabao; Kong, Yaozhong*佛山市第一人民医院; 南方医科大学
Turkish Journal Of Medical Sciences2021DOI: 10.3906/sag-2104-177
2被引9阅读
引用收藏
分享

摘要

Background/aim: This meta-analysis comprehensively investigated the efficacy and safety of rituximab (RTX) in patients with idiopathic membranous nephropathy (IMN). Materials and methods: We searched the MEDLINE, EMBASE and Cochrane Registry of Controlled Trials databases from January 2000 to January 2020. Studies evaluating the efficacy and safety of RTX in the treatment of IMN with nephrotic syndrome (NS) were included. Results: Nine studies (total of 357 patients) were included in the meta-analysis. The pooled complete response and overall response (OR) rates at 12 months were 13.2% [95% confidence interval (CI), 0.09-0.18] and 60% (95% CI, 0.48-0.72), and those at 24 months were 27.8% (95% CI, 0.22-0.34) and 66% (95% CI, 0.6-0.72), respectively. The pooled OR rates for the low-, standard-, and high-dose groups were 39.3%, 64%, and 60%, respectively, and those for the first-line and second-line groups were 58% and 54%, respectively. Conclusion: Treatment of IMN with RTX has comparable efficacy to other immunosuppressive treatments (ISTs). RTX has the advantages of no requirement for steroids and lower rates adverse event and relapse rates. Patients who relapse or are resistant to other IST agents also respond to RTX. RTX-based regimens and other B-cell-targeted therapies may represent the future of IMN therapy.

学科与关键词

关键词
Rituximabmembranous nephropathyimmunosuppressive treatmentmeta-analysis
相关
加载中…
  • Clinical efficacy and safety of rituximab with membranous nephropathy: a meta-analysis
    Zhong, Hongzhen; Li, Hong-Yan; Zhou, Tianbiao*; Zhong, ZhiqingArchives of Medical Science, 2023, 19(2): 411-419.
  • Rituximab therapy in adults with steroid-dependent nephrotic syndrome
    Zhong, Hongzhen; Li, Hong-Yan; Zhou, Tianbiao*; Weng, WenjuanArchives of Medical Science, 2023, 19(3): 577-585.
  • Astragalus membranaceus formula for moderate-high risk idiopathic membranous nephropathy: A meta-analysis
    Wang, Dan; Wang, Lijuan; Zhang, Mingrui; Li, Ping; Zhang, Qinghua; Bao, Kun*Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries, 2023, 102(9).
查看全部 →

发表信息

论文状态
公开发表
期刊
Turkish Journal Of Medical Sciences
发表日期
2021
卷期
第 51 卷, 第 6 期
页码
2870-2880
DOI
10.3906/sag-2104-177
语言
ENGLISH
期刊收录
NSL
期刊等级
4区
成果收录
SCIE

作者

  • Y

    You, Lu (第一作者)

    first peoples hosp foshan

  • Y

    Ye, Peiyi

    first peoples hosp foshan

查看全部 5 位作者收起作者
  • X

    Xiao, Guanqing

    first peoples hosp foshan

  • L

    Liang, Jiabao

    southern med univ

  • K

    Kong, Yaozhong (通讯)

    first peoples hosp foshan

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417